Silybin B

Overview

Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK / p38 MAPK signaling. Silybin B can reduce Cisplatin ( HY-17394 )-induced neuronal DNA damage and apoptosis . Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Amyloid-β | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > JNK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-N7046
• CAS No.: 142797-34-0
• Molecular Formula: C25H22O10
• Molecular Weight: 482.44
• Purity: 99.90%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution
• Availability: In-stock

Source

Original product source